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OBJECTIVES We sought to examine if clopidogrel treatment initiated before coronary stenting improved
clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor.
BACKGROUND Antiplatelet therapy plays a pivotal role in contemporary percutaneous coronary interventions
(PCI).
METHODS Outcomes among 4,809 patients randomized to tirofiban or abciximab during PCI with stent
placement were compared according to whether they received 300 mg of clopidogrel before
PCI (93.1%) versus immediately after the procedure.
RESULTS The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target
vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6.6% vs.
10.4%, p  0.009), mainly because of reduction of MI (6.0% vs. 9.5%, p  0.012). The
benefit of clopidogrel pretreatment was sustained at six months (death, MI, any TVR: 14.6%
vs. 19.8%, HR  0.71, p  0.010), and this was due mainly to lowering of death and MI
(7.8% vs. 13.0%, p  0.001). At one year, clopidogrel pretreatment was associated with a
lower mortality rate (1.7% vs. 3.6%, p  0.011). Because clopidogrel pretreatment was not
randomized, multivariable and propensity analyses were performed. After adjusting for
baseline heterogeneity, clopidogrel pretreatment was an independent predictor for death or
MI at 30 days (HR  0.63, p  0.012) and at six months (HR  0.61, p  0.003), and
survival at one year (HR  0.53, p  0.044). No excess in 30-day bleeding events was noted
with clopidogrel pretreatment.
CONCLUSIONS Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa
inhibitor, clopidogrel pretreatment is associated with a reduction of death and MI irrespective
of the type of GP IIb/IIIa inhibitor used. (J Am Coll Cardiol 2003;42:1188–95) © 2003
by the American College of Cardiology Foundation
Antiplatelet therapy plays a pivotal role in percutaneous
coronary interventions (PCI). The use of aspirin during
coronary balloon angioplasty reduces the incidence of acute
See page 1196
thrombotic complications (1–3). When added to aspirin,
intravenous glycoprotein (GP) IIb/IIIa receptors further
improve clinical outcome during elective, urgent, and emer-
gency PCI (4–10). The administration of ticlopidine after
coronary stenting also improves clinical outcome (11–18).
In a subanalysis of the Evaluation of Platelet IIb/IIIa
Inhibitor for Stenting (EPISTENT) trial (19), ticlopidine
given before PCI was associated with a reduction of subse-
quent major adverse cardiac events during the first year.
However, this benefit was evident only among patients
randomly assigned to placebo and not among those patients
receiving the GP IIb/IIIa inhibitor abciximab.
Clopidogrel is a selective, irreversible adenosine diphos-
phate (ADP) receptor antagonist (20). It has a more rapid
platelet anti-aggregatory effect than ticlopidine, and
achieves near maximal platelet inhibition within 2 to 6 h
using a 300 mg oral loading dose (21–23). Given after PCI,
the combination of aspirin and clopidogrel appears to have
a superior safety profile as compared with aspirin plus
ticlopidine (24–28). In a recent substudy from the Clopi-
dogrel in Unstable Angina to Prevent Recurrent Events trial
(PCI-CURE) (29), clopidogrel treatment before PCI (with
or without stent placement) was associated with improved
outcome, though less than one-fourth of the patients
received IIb/IIIa inhibitors. Because GP IIb/IIIa antago-
nists provide potent inhibition of platelet aggregation and
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have become a standard pharmacologic adjunct in contem-
porary PCI, whether clopidogrel pretreatment provides
important additional benefits among patients receiving IIb/
IIIa inhibitors remains uncertain. Therefore, we examined
the impact of clopidogrel pretreatment among patients in
the Do Tirofiban and ReoPro Give Similar Efficacy Out-
come Trial (TARGET) (30).
METHODS
Study protocol. The design and methods of TARGET
have been previously detailed (30,31). In brief, 4,809 pa-
tients undergoing elective or urgent PCI-stent of native
coronary vessels or bypass grafts were enrolled between
December 1999 and August 2000 in 149 hospitals in North
America, Australia, and Europe. Patients were randomized
in a double-blind, double-dummy fashion to receive a bolus
and infusion of either abciximab or tirofiban. All patients
received 250 to 500 mg of aspirin within 24 h before the
procedure and 75 to 325 mg/day following the procedure. A
loading dose of 300 mg of clopidogrel at least 2 to 6 h before
the procedure was recommended. Alternatively, the same
dose of clopidogrel could be given just before the PCI
procedure if it were performed immediately following diag-
nostic angiography. The timing of clopidogrel administra-
tion was at the interventional cardiologists’ discretion.
Patients who received clopidogrel before either abciximab or
tirofiban was given were categorized into the clopidogrel
pretreatment group. Otherwise, a 300-mg loading dose of
clopidogrel was to be given as early as possible after the
procedure. Clopidogrel was continued for 30 days after PCI
at a dose of 75 mg daily. At the time of procedure, heparin
was administered to achieve an activated clotting time250
s. Interventional procedures were performed as per institu-
tional standard.
Study end points. The primary end point of TARGET
was the composite of death, nonfatal myocardial infarction
(MI), or urgent TVR within 30 days of the index procedure.
Prespecified secondary end points included the composite of
death, nonfatal MI, or any TVR at six months and mortality
at one year. Treatment assignment remained blinded to one
year. The definition of MI during index hospitalization and
to six months was described previously (30). Target vessel
revascularization was defined as any repeat revascularization
of the vessel treated during the index procedure. For the
safety analysis, the end points of major and minor bleeding
were defined using the Thrombolysis In Myocardial Infarc-
tion (TIMI) criteria (32). End points were reported by
investigators, and were reviewed and adjudicated by an
independent Clinical Events Committee.
Statistical analysis. All patients were categorized accord-
ing to whether they received pretreatment with clopidogrel
or not. The time of first clopidogrel administration was
recorded, and subanalysis was performed separating patients
into pretreatment intervals: no pretreatment; treatment 0 to
2 h, 2 to 6 h, or6 h before PCI (time zero defined as when
IIb/IIIa inhibitor bolus was given). The demographic,
procedural, and safety data are reported as percentages for
discrete variables, and as means  1 SD for continuous
variables. Comparisons of the baseline characteristics be-
tween clopidogrel pretreatment and no pretreatment were
made by means of chi-square statistics for categorical
variables and Mann-Whitney-Wilcoxon tests for continu-
ous variables. Fisher’s exact test was used to compare
infrequent events such as major and minor bleeding.
Kaplan-Meier methods were used to estimate end points at
30 days, 6 months, and 1 year, and log-rank tests were used
to compare the clopidogrel pretreatment and no pretreat-
ment groups.
Because the timing of clopidogrel administration relative
to the PCI procedure was not randomized, a propensity
analysis was performed (33) to adjust for potential bias
inherent in treating patients with clopidogrel before rather
than following PCI. Based on the individual demographic
and preprocedural clinical characteristics, a propensity score
was developed for each patient using a multivariable logistic
regression model in order to estimate the probability of
clopidogrel pretreatment. Covariates that were tested in the
model included demographic characteristics (age, gender,
race, body mass index), cardiovascular risk factors (cigarette
smoking, hypertension, diabetes, hypercholesterolemia, and
family history of coronary artery disease), cardiovascular and
major noncardiac comorbidities (prior history of coronary
bypass, PCI, MI, heart failure, stroke, peripheral arterial
disease, gastrointestinal disorders, and bleeding diathesis),
acuity of presentation (recent Q-wave MI, non–Q-wave
MI, unstable angina, and stable angina), and concomitant
medication use (aspirin, angiotensin-converting enzyme
inhibitors, beta-blockers, calcium-receptor antagonist,
lipid-lowering agent, nitrates, anti-inflammatory agents,
anti-ulcerants, insulin, and hypoglycemic agents). To exam-
ine the impact of clopidogrel pretreatment on outcome, the
propensity score was entered into the Cox proportional
hazards model as a continuous variable along with potential
covariates that might affect outcome. These variables in-
Abbreviations and Acronyms
ACS  acute coronary syndrome
ADP  adenosine diphosphate
CREDO  Clopidogrel for Reduction of Events
During Observation
EPISTENT  Evaluation of Platelet IIb/IIIa Inhibitor
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GOLD  Assessing Ultegra-AU Study
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PCI  percutaneous coronary intervention
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cluded those entered into the propensity score model, and
the procedural variables (assigned study drug, prior heparin
use, number of diseased vessels, target vessel(s), lesion
length, multivessel PCI, pre-TIMI flow, U.S. vs. non-U.S.
enrollment). A p value of 0.05 was considered statistically
significant in all analyses.
RESULTS
Of the 4,809 patients enrolled, 4,477 (93.1%) were given
clopidogrel before PCI. Baseline clinical characteristics of
the two groups are shown in Table 1. Of note, the two
groups were similar regarding cardiovascular risk profile, the
prevalence of comorbidities, and indication for coronary
revascularization. Compared with patients who did not
receive clopidogrel before PCI, clopidogrel-pretreated pa-
tients were more likely to receive aspirin, beta-blockers,
calcium-channel blockers, and lipid-lowering therapy before
their procedures. Among the patients who received pre-
treatment, 2,535 patients (56.6%) received the loading dose
within 2 h before procedures, 1,216 patients (27.2%) within
2 to 6 h, and 726 patients (16.2%) for6 h before the index
procedure. The mean duration from clopidogrel adminis-
tration to initiation of PCI was 2.1 h.
30-day outcomes. The primary composite end point of
death, MI, or urgent TVR at 30 days occurred in 10.4% of
patients without pretreatment and in 6.6% of patients with
clopidogrel pretreatment (p  0.009, Table 2). The benefit
of clopidogrel pretreatment was predominantly due to a
reduction in MI (9.5% vs. 6%, p  0.012). There was no
significant difference in the triple end point event rates
between patients who received pretreatment for 0 to 2 h and
those who were pretreated for 2 to 6 h (6.5% vs. 7.7%,
respectively; p  0.198). Compared with patients who did
not receive clopidogrel until after PCI, those who were
pretreated 0 to 6 h before the procedure had a 34% lower
composite event rate (6.9% vs. 10.4%, p  0.021). Further-
more, as compared with those who were pretreated for 6
h, patients who were clopidogrel-loaded for 6 h before
PCI had a 29% lowering in 30-day events (6.9% vs. 4.9%, p
 0.045); this difference was due mainly to fewer MI events
(6.3% vs. 4.2%, p  0.028).
Figure 1 illustrates the rates of primary end point accord-
ing to clopidogrel pretreatment and IIb/IIIa drug assign-
ment. When given to patients randomized to tirofiban
therapy, clopidogrel pretreatment relatively reduced the
30-day event rate by 43%, from 12.8% to 7.3% (p  0.017).
Likewise, patients who were pretreated with clopidogrel and
received abciximab had a 30% relative reduction in the
composite event rate (from 8.4% to 5.9%, p  0.168)
compared with abciximab without clopidogrel pretreatment.
Whereas the overall TARGET study showed a 26% relative
risk reduction in primary end point with abciximab as
compared with tirofiban, the superiority of abciximab was
attenuated among patients who received clopidogrel pre-
treatment (Table 3).
Table 1. Baseline Clinical and Target Lesion Characteristics of
Patients Who Were Pretreated and Those Who Were Not
Pretreated With Clopidogrel
Clopidogrel
Pretreatment
(n  4,477)
No
Clopidogrel
Pretreatment
(n  332) p
Age, yrs 62.3  10.9 62.5  11.3 0.954
Female, % 26.4 28.3 0.441
Weight, kg 86.0  17.6 87.6  18.5 0.121
Caucasian, % 91.4 88.0 0.034
Risk factors, %
Cigarette smoking 21.8 24.2 0.306
Diabetes mellitus 23.3 22.0 0.579
Hypertension 64.5 68.9 0.110
Hypercholesterolemia 75.1 72.0 0.214
Family history of coronary
artery disease
54.7 53.1 0.577
Medical history, %
Coronary bypass grafting 17.2 13.3 0.064
Prior PCI 29.7 27.5 0.404
Heart failure 9.7 11.5 0.292
Myocardial infarction 39.6 36.6 0.267
Prior stroke 2.7 2.4 0.722
Peripheral arterial disease 9.6 11.5 0.265
Gastrointestinal disorders 23.9 24.8 0.719
Bleeding disorders 0.8 1.2 0.330
Medications, %
Aspirin (within 24 h) 97.3 93.6  0.001
ACE inhibitors 36.9 32.5 0.113
Beta-blockers 66.0 57.8 0.003
Calcium-channel antagonists 31.7 24.4 0.006
Lipid-lowering agents 60.7 48.8  0.001
Nitrates 59.5 58.7 0.789
Thombolytics during index
admission
5.3 4.2 0.395
Anti-inflammatory agents 15.1 16.9 0.393
Anti-ulcerants 32.5 29.8 0.310
Insulin 8.2 8.1 0.944
Oral hypoglycemic agents 16.6 15.4 0.573
Randomized to abciximab, % 49.8 54.2 0.123
Indication for PCI, % 0.541
Q-wave MI 5.5 5.4
Non–Q-wave MI 10.3 9.3
Unstable angina 46.9 51.5
Stable angina and others 37.3 33.8
Lesion location
Left anterior descending artery 42.6 42.3 0.920
Circumflex artery 28.1 29.3 0.643
Right coronary artery 37.3 38.1 0.776
Left main coronary artery 1.3 1.8 0.454
Bypass graft 6.1 5.4 0.625
Severity of stenosis before PCI 87.6  9.7% 88.4  9.8% 0.117
Lesion length, % 0.912
10 mm 24.9 25.2
10–20 mm 59.2 58.2
20 mm 15.9 16.7
Left ventricular ejection fraction 0.244
50% 72.6 73.1
30%–50% 25.0 22.9
30% 2.5 4.0
ACE  angiotensin-converting enzyme; MI  myocardial infarction; PCI 
percutaneous coronary intervention.
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Six-month outcomes. Clopidogrel pretreatment was asso-
ciated with a reduction in the composite of death, MI, or
any TVR at six months (14.6% vs. 19.8%, p  0.010),
mainly due to a reduction in the composite of death or
nonfatal MI (Table 2). The death or MI composite was 38%
lower among those given clopidogrel 0 to 6 h before PCI as
opposed to after the procedure (8.1% vs. 13.0%, p 0.003).
This rate was an additional 26% lower for patients pre-
treated 6 h before PCI (6.0% vs. 8.1%, p  0.051). The
impact of clopidogrel pretreatment appeared more evident
among patients randomized to tirofiban than abciximab,
and this benefit predominantly occurred as a reduction in
the death or MI composite (Table 3, Fig. 2). Comparing
clopidogrel pretreatment with no pretreatment, the death or
MI composite was reduced from 15.5% to 8.4% (hazard
ratio [HR]  0.54, p  0.004) in the tirofiban group and
from 10.9% to 7.2% (HR  0.66, p  0.076) in the
abciximab group.
One-year mortality. Clopidogrel given before the index
procedure was associated with a significant mortality reduc-
tion within the first year (1.7% vs. 3.6%, HR  0.47, p 
0.011). This was mainly due to the reduction in mortality in
the tirofiban group (1.8% vs. 4.6%, p  0.012), though a
small benefit may have existed in the abciximab group (1.7%
Table 2. Clinical End Points at 30 Days, 6 Months, and 1 Year According to
Clopidogrel Pretreatment
Clopidogrel
Pretreatment
n  4,477 (%)
No Clopidogrel
Pretreatment
n  332 (%)
Hazard Ratio
(95% CI) p
30 days
Death 19 (0.4) 3 (0.9) 0.46 (0.14–1.55) 0.196
MI 265 (6.0) 31(9.5) 0.62 (0.43–0.91) 0.012
Death/MI 277 (6.2) 33 (10.1) 0.61 (0.43–0.88) 0.007
Urgent TVR 33 (0.7) 3 (0.9) 0.80 (0.25–2.61) 0.711
Death, MI, or urgent TVR 292 (6.6) 34 (10.4) 0.63 (0.44–0.89) 0.009
6 months
Death 43 (1.0) 8 (2.6) 0.39 (0.18–0.82) 0.010
MI 315 (7.1) 35 (10.7) 0.65 (0.46–0.92) 0.015
Death/MI 344 (7.8) 42 (13.0) 0.59 (0.43–0.81) 0.001
Any TVR 373 (8.7) 29 (9.4) 0.92 (0.63–1.34) 0.647
Death, MI, or any TVR 638 (14.6) 63 (19.8) 0.71 (0.55–0.92) 0.010
1 year mortality 76 (1.7) 12 (3.6) 0.46 (0.25–0.85) 0.011
Hazard ratios and p values are unadjusted.
CI  confidence interval; MI  myocardial infarction; TVR  target vessel revascularization.
Figure 1. Kaplan-Meier curves of 30-day composite of death, nonfatal myocardial infarction (MI), and urgent target vessel revascularization (TVR) in
patients according to clopidogrel pretreatment and assignment of glycoprotein IIb/IIIa inhibitors. The clinical benefit of clopidogrel pretreatment was
present regardless of which IIb/IIIa agent was used. Abciximab was superior to tirofiban in terms of 30-day composite end point; however, the extent
appears attenuated in the presence of clopidogrel pretreatment.
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vs. 2.8%, p  0.257). For patients who did not receive
clopidogrel pretreatment, abciximab administration was as-
sociated with a numerically lower but statistically similar
mortality rate at one year compared with tirofiban (2.8% vs.
4.6%, p  0.390).
Multivariable analysis. Within the propensity score anal-
ysis, variables that independently predicted the use of
clopidogrel before PCI were (in descending order) prescrip-
tion of lipid-lowering agents, concomitant aspirin use and
history of angina. The following variables were also included
in the logistic model using intersections statistics to develop
the final propensity score: BMI 30, race, hypertension,
and use of prior medications such as angiotensin-converting
enzyme inhibitors, beta-blockers, and calcium channel
blockers. The goodness-of-fit for the propensity score as
assessed by the c-statistic was 0.64. Using Cox proportional
hazards modeling to adjust for potential variables and the
propensity of prescribing clopidogrel before the procedure,
clopidogrel pretreatment remained an independent predic-
tor for a lower composite of death or MI at 30 days and six
months. Other independent correlates for death or MI at 30
days and 6 months are provided in Table 4.
Not surprisingly, the strongest predictors for outcome
included advanced age, acuity of disease (acute coronary
syndrome [ACS]), and extent of atheroma (lesion length
and number of vessels revascularized). Adding statistical
interactions to several proportional hazard models, clopi-
dogrel continued to provide independent predictive value.
Table 3. Influence of Clopidogrel Pretreatment on Relative Efficacy of Tirofiban Versus Abciximab on Various End Points
Clopidogrel Pretreatment (n  4,477)
p
No Clopidogrel Pretreatment (n  332)
p
Abciximab
n  2,231 (%)
Tirofiban
n  2,246 (%)
Hazard Ratio*
(95% CI)
Abciximab
n  180 (%)
Tirofiban
n  152 (%)
Hazard Ratio*
(95% CI)
30 days
Death 8 (0.4) 11 (0.5) 0.73 (0.29–1.81) 0.497 2 (1.2) 1 (0.7) 1.72 (0.16–20.00) 0.655
MI 118 (5.3) 147 (6.6) 0.81 (0.63–1.03) 0.080 13 (7.2) 18 (12.1) 0.61 (0.30–1.23) 0.167
Death/MI 124 (5.6) 153 (6.9) 0.81 (0.64–1.03) 0.087 14 (7.8) 19 (12.8) 0.62 (0.31–1.23) 0.170
Urgent TVR 15 (0.7) 18 (0.8) 0.83 (0.42–1.67) 0.609 1 (0.6) 2 (1.4) 0.42 (0.04–4.76) 0.470
Death, MI, or urgent TVR 130 (5.9) 162 (7.3) 0.81 (0.64–1.01) 0.065 15 (8.4) 19 (12.8) 0.67 (0.33–1.32) 0.234
6 months
Death 21 (1.0) 22 (1.0) 0.96 (0.53–1.75) 0.891 4 (2.4) 4 (2.9) 0.91 (0.23–3.57) 0.883
MI 143 (6.5) 172 (7.8) 0.83 (0.67–1.04) 0.108 16 (9.1) 19 (12.6) 0.71 (0.37–1.39) 0.324
Death/MI 159 (7.2) 185 (8.4) 0.86 (0.69–1.06) 0.167 19 (10.9) 23 (15.5) 0.70 (0.38–1.30) 0.856
Any TVR 193 (9.0) 180 (8.3) 1.08 (0.88–1.32) 0.470 15 (9.3) 14 (9.5) 0.96 (0.46–2.00) 0.909
Death, MI, or any TVR 314 (14.4) 324 (14.7) 0.97 (0.83–1.34) 0.688 31 (18.3) 32 (21.6) 0.83 (0.51–1.35) 0.459
1-year mortality 37 (1.7) 39 (1.8) 0.95 (0.61–1.49) 0.840 5 (2.8) 7 (4.6) 0.61 (0.19–1.92) 0.390
*Refers to the unadjusted hazard ratios for abciximab vs. tirofiban.
Abbreviations as in Table 2.
Figure 2. Kaplan-Meier curves of composite of death and nonfatal myocardial infarction (MI) to six months, based on the use of clopidogrel pretreatment
and assignment of glycoprotein IIb/IIIa inhibitors.
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Interestingly, in one analysis, the use of antidepressants
contributed to the overall model (chi-squared  6), and
when adding the interaction term preprocedural clopidogrel
 antidepressant use, the separate contribution of clopi-
dogrel pretreatment was decreased whereas the contribution
of antidepressants was increased. At one-year follow-up,
clopidogrel pretreatment remained an independent predic-
tor for survival (HR  0.53; 95% CI, 0.29 to 0.98; p 
0.044) after adjusting for the study drug treatment, age,
gender, body mass index, presentation acuity, cardiac and
vascular comorbidities, cardiovascular risk factors, bleeding
disorders, and medication use.
Bleeding. The incidence of major and minor bleeding, and
frequency of transfusion according to clopidogrel pretreat-
ment, are listed in Table 5. The frequency of these compli-
cations was low, and there was no significant increase in
bleeding events among patients treated with clopidogrel
before undergoing PCI with adjunctive GP IIb/IIIa
inhibitors.
DISCUSSION
Among PCI patients undergoing stent placement with
adjunctive aspirin and a GP IIb/IIIa inhibitor, clopidogrel
administered as an oral loading dose before the procedure
was associated with superior clinical outcome, which was
evident within 24 to 48 h after the procedure and was
sustained at 6 months. Although the outcome with 6 h of
pretreatment was more favorable than that of 0 to 6 h of
pretreatment, clopidogrel loading within 6 h before the
procedure was also associated with significantly better out-
come as compared with no pretreatment. Clopidogrel pre-
treatment was predominantly associated with a reduction in
ischemic events (MI), though its benefit appears to extend
to mortality reduction at one year. These associations
remained markedly significant following adjustment for
baseline clinical and procedural characteristics, as well as the
propensity for receiving preprocedural clopidogrel. The
observations remained significant even when broadening the
composite six-month outcome to include target vessel re-
vascularization.
The efficacy of thienopyridine pretreatment before PCI
has been reported (19,29,34). In the EPISTENT trial (19),
pretreatment with a thienopyridine (ticlopidine) was asso-
ciated with a reduction of major adverse cardiac events,
though the benefit was not seen among patients randomized
to IIb/IIIa inhibition. In the PCI-CURE study (29), the
duration of clopidogrel pretreatment was markedly longer
than in the current study (days versus hours), but cardiac
enzymes were not routinely measured postprocedure. The
presence of an interaction between clopidogrel pretreatment
and IIb/IIIa inhibitor use could not be readily assessed
because IIb/IIIa inhibitors were administered to a minority
of PCI-CURE patients. The results of the Clopidogrel for
Reduction of Events During Observation (CREDO) trial
showed that clopidogrel pretreatment before PCI reduced a
28-day composite of death, MI, or urgent revascularization
18.5% (from 8.3% to 6.8%, p  0.23), though the benefit
did not reach statistical significance perhaps owing to
sample size (35). However, similar to the PCI-CURE trial,
less than one-fourth of the CREDO patients received
planned GP IIb/IIIa inhibitor treatment, and a similarly
small percentage of patients were treated with IIb/IIIa
therapy as part of a bailout strategy. Consistent with the
early report from CREDO, we observed the lowest adverse
event rate among those with 6 h of clopidogrel pretreat-
ment. Given the large sample size in TARGET, it is
impressive that treatment with clopidogrel prior to coronary
stenting was associated with incremental benefit in the
presence of both aspirin and a IIb/IIIa inhibitor. This
benefit seems extraordinary and likely reflects the impor-
tance of inflammation and platelets in PCI associated with
vascular injury (36).
The mechanism of benefit with clopidogrel pretreatment
deserves particular attention. When combined with aspirin
therapy, clopidogrel provides synergistic antiplatelet effects
Table 4. Independent Predictors for Death or MI After
Coronary Stenting
Characteristics
Hazard
Ratio
95% Confidence
Interval p
30 days
Clopidogrel pretreatment 0.63 0.43–0.90 0.012
RCA intervention 0.75 0.59–0.95 0.017
Abciximab vs. tirofiban 0.80 0.64–1.00 0.048
Propensity score 0.99 0.72–1.38 0.979
Age  65 years 1.53 1.22–1.91  0.001
Multivessel PCI 1.60 1.22–2.10 0.001
Maximal lesion length* 1.86 1.55–2.24  0.001
6 months
Clopidogrel pretreatment 0.61 0.44–0.84 0.003
RCA intervention 0.78 0.63–0.97 0.022
Propensity score 0.99 0.75–1.35 0.977
Age  65 years 1.31 1.07–1.61 0.008
Acute coronary syndrome 1.39 1.10–1.75 0.005
Heart failure 1.51 1.14–2.00 0.005
Multivessel PCI 1.51 1.18–1.93 0.001
Maximal lesion length* 1.68 1.43–1.98  0.001
*Classified as 10 mm vs. 10–20 mm vs. 20 mm.
MI  myocardial infarction; PCI  percutaneous coronary intervention; RCA 
right coronary artery.
Table 5. Incidence of Bleeding and Transfusion During
Index Hospitalization
Clopidogrel
Pretreatment
(n  4,477)
No Clopidogrel
Pretreatment
(n  332) p
Major or minor bleeding, % 4.3 3.9 0.718
Major bleeding, % 0.8 0.9 0.754
Minor bleeding, % 3.6 3.3 0.821
Transfusion, %
Packed red blood cells 1.3 0.9 0.800
Platelet 0.4 0.9 0.191
Plasma 0.2 0.3 0.475
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via concurrent inhibition of ADP and thromboxane A2
pathways (37,38). Based on the results from the Assessing
Ultegra-AU (GOLD) study (39), optimal PCI outcome
regarding death or MI was observed with 95% inhibition
of platelet aggregation at 10 min after initiation of therapy.
Interestingly, using ADP-induced platelet aggregation test-
ing, the tirofiban regimen used in TARGET produced
70% platelet inhibition during the first 60 min of proce-
dure, in contrast to abciximab, which consistently achieved
90% inhibition during this time (40,41). As such, clopi-
dogrel pretreatment may lower the risk of myocardial
necrosis during the window of vulnerability following the
tirofiban bolus and before the drug infusion can achieve
adequate plasma levels (40,42,43). Even among abciximab-
receiving patients with PCI, the current analysis suggests
that clopidogrel pretreatment provides benefit.
Additionally, it is possible that a benefit of clopidogrel
pretreatment is separately related to a reduction in platelet
activation and inflammation. Elevated C-reactive protein
(CRP) level has been linked to the risk of cardiovascular
death and MI after PCI (44,45). This association was
blunted in the presence of clopidogrel pretreatment (46),
implying that patients with elevated baseline CRP may
derive particular benefit from clopidogrel pretreatment.
Indeed, formation of platelet-leukocyte aggregates was re-
duced by clopidogrel through lowering CD62 expression in
an in vitro model (47), suggestive of a link between platelet
activation and inflammation. Although patients with ACS
are more likely to have an associated heightened inflamma-
tory state, both ACS and non-ACS patients received similar
benefit from clopidogrel pretreatment in the TARGET trial
(48).
Study limitations. Clopidogrel pretreatment in this study
was not randomized. Despite the use of contemporary
statistical methods to adjust for imbalances between the
pretreatment and no pretreatment groups, unmeasured con-
founders might have influenced the decision regarding the
timing of clopidogrel administration (selection bias), and
the intermediate goodness-of-fit of the propensity model
(C-statistic 0.64) may reflect this. Alternatively, the model’s
fit may only be modest because the covariates were already
fairly balanced between the groups. It is worth noting that
the major determinants of early and intermediate outcome
after PCI, such as age, left ventricular function, indication
for procedure, and diabetic status were similar between the
two study groups. As noted in Table 4, the propensity score
itself was not independently predictive of outcome. This
suggests that decisions regarding pretreatment with clopi-
dogrel were not systematically biased according to baseline
prognostic profiles. Finally, the duration of clopidogrel
therapy before the index procedure was variable among
patients. The quick onset of effect for the 300-mg bolus
dosing reduces the effect of dose duration, although patients
treated more than 6 h in advance had the best outcome.
However, by including all patients who received clopidogrel
regardless of how soon before beginning PCI, our observa-
tions should only underestimate the effect of clopidogrel
pretreatment.
Conclusions. Our analysis suggests that in addition to
platelet inhibition provided by aspirin and GP IIb/IIIa
inhibitors, administration of clopidogrel before coronary
stenting further reduces ischemic complications during both
elective and urgent PCI procedures. Even a relatively brief
period of clopidogrel pretreatment, such as a loading dose
several hours before PCI, is associated with improved
outcomes. Pretreatment for 6 h was associated with even
greater antithrombotic protection and was found to be safe.
This triple therapy antiplatelet regimen should be consid-
ered for all PCI-stent patients.
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